Ulka Vaishampayan

Jun 21, 2024 | urotoday.com | Ulka Vaishampayan

Read the Full Video TranscriptAndrea Miyahira: Hi, I am Andrea Miyahira at the Prostate Cancer Foundation. Thank you for joining me today. With me is Dr. Ulka Vaishampayan, a professor and medical oncologist at the University of Michigan. She'll be joining us today to talk about her many roles as the leading woman in science. Dr. Vaishampayan, thank you so much for joining me today. Ulka Vaishampayan: Thank you for this invite, Andrea.

Dec 24, 2023 | cco.amegroups.org | Ulka Vaishampayan

Have a website account?Log In orRegister for exclusive website content. Home / Vol 12, No 6 (December 31, 2023) / Global efficacy and clinical application of androgen receptor inhibitors in metastatic prostate cancer PDF 340 views Full Text 9 views Peer Review File 25 views COI Form 22 views

Dec 1, 2023 | onclive.com | Ulka Vaishampayan

Ulka Nitin Vaishampayan, MBBS, director, the Phase I Program at Rogel Cancer Center, professor, internal medicine, University of Michigan, discusses the rationale for conducting the phase 3 SWOG 1931 trial (NCT04510597) in patients with advanced renal cell carcinoma (RCC). Vaishampayan begins by stating that she presented the rationale and design of the SWOG 1931 trial, also known as the PROBE study, at the 2023 International Kidney Cancer Symposium (IKCS).

Aug 29, 2023 | onclive.com | Rana R. McKay |Arash Rezazadeh Kalebasty |Sumit K. Subudhi |Scott T. Tagawa |Ulka Vaishampayan

CAR T-Cell Therapy in Metastatic CRPC and Future Directions in CareClosing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Aug 29, 2023 | onclive.com | Rana R. McKay |Arash Rezazadeh Kalebasty |Sumit K. Subudhi |Scott T. Tagawa |Ulka Vaishampayan

Novel ADCs Must Keep Up With Moving Targets in Metastatic Breast CancerDr Massarelli on Addressing Unmet Needs in SCLCNK T-Cell Agonist Under Investigation in Combination With Pembrolizumab in Melanoma and NSCLC